Under lens device incorporating hyaluronic acid
US-2024342468-A1 · Oct 17, 2024 · US
US10617563B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10617563-B2 |
| Application number | US-201615217559-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 22, 2016 |
| Priority date | Jul 22, 2015 |
| Publication date | Apr 14, 2020 |
| Grant date | Apr 14, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A prosthesis comprising a water-dissolvable coating. A prosthesis for a lacrimal canaliculus comprising a swellable punctal plug with a proximal end and a distal end, with the plug comprising a water-dissolvable biocompatible coating on the distal and/or the proximal end. Materials and methods for making and using the same. A prosthesis for placement in or across natural or prosthetic lumens, ostia, ducts, sinus, or sphincters, the prosthesis comprising a coating. The prosthesis can further provide a depot for sustained drug delivery to tissue.
Opening claim text (preview).
The invention claimed is: 1. A prosthesis for passage into an opening in a tissue, the prosthesis comprising a swellable punctal plug with a body having a proximal end and a distal end, wherein the plug, when placed in physiological solution and allowed to freely expand, swells from 10% to 300% in volume, the prosthesis further comprising a water-dissolvable coating on the swellable punctal plug that forms an ellipsoid shape such that the ellipsoid covers a portion of the body and the distal end and continuously extends from 0.1 mm to 3 mm beyond the distal end to provide a tip for the prosthesis. 2. The prosthesis of claim 1 wherein the coating comprises a water soluble material. 3. The prosthesis of claim 2 wherein the water soluble material consists essentially of a hydrophilic polymer. 4. The prosthesis of claim 2 wherein the water soluble material comprises a hydrophilic polymer that comprises polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, cellulose, polyacrylic acid, polyethyleneimine, peptide, or polysaccharide. 5. The prosthesis of claim 1 wherein the coating encapsulates the punctal plug. 6. The prosthesis of claim 1 wherein the plug and/or coating further comprises a therapeutic agent. 7. The prosthesis of claim 6 wherein the agent is for treatment of an ocular condition. 8. The prosthesis of claim 7 wherein the ocular condition is age-related macular degeneration (AMD) cystoid macular edema (CME), diabetic macular edema (DME), posterior uveitis, diabetic retinopathy, or glaucoma. 9. The prosthesis of claim 8 wherein the agent comprises anti-VEGF, a VEGFR1 inhibitor, a VEGFR2 inhibitor, a VEGFR3 inhibitor, anti-PDGF, anti-PDGF-R, a PDGFRβ inhibitor, an anti-angiogenic agent, sunitinib, E7080, Takeda-6d, tivozanib, regorafenib, sorafenib, pazopanib, axitinib, nintedanib, cediranib, vatalanib, motesanib, a macrolide, sirolimus, everolimus, a tyrosine kinase inhibitor (TKI), imatinib, gefinitib, toceranib, erlotinib, nilotinib, bosutinib neratinib, lapatinib, nepafenac, tacrolimus, moxifloxacin, dexamethasone, travoprost, a steroid, a fluoroquinolone, a prostaglandin analog, a prostamide, or an mTOR receptor inhibitor. 10. The prosthesis of claim 1 wherein the coating further comprises a visualization agent detectable by an unaided human eye. 11. The prosthesis of claim 1 wherein the coating is a solid at a physiological temperature and has a melting point in a range from 40 to 100 degrees Celsius. 12. The prosthesis of claim 1 wherein the coating essentially dissolves in a physiological solution in no more than 15 minutes. 13. The prosthesis of claim 1 wherein the coating does not contact the proximal end. 14. The prosthesis of claim 13 wherein the coating comprises a visualization agent to indicate an orientation of the punctal plug. 15. The prosthesis of claim 1 wherein the tip has a rounded terminus.
PE, i.e. polyethylene · CPC title
Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title
Apparatus for restoration of tear ducts · CPC title
Materials at least partially X-ray or laser opaque · CPC title
using gamma-ray · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.